{
    "title": "107_s754",
    "content": "The \"Drug Competition Act of 2002\" aims to address the increasing prescription drug prices by promoting competition among companies manufacturing brand name and generic drugs, ultimately reducing drug expenditures for American citizens. The Drug Competition Act of 2002 aims to provide timely notice to the Department of Justice and the Federal Trade Commission regarding agreements between companies with patent rights on brand name drugs and companies that could manufacture generic versions. This is to enhance the enforcement of antitrust and competition laws in the United States. The Drug Competition Act of 2002 defines key terms related to drug approval and enforcement, such as ANDA, Assistant Attorney General, brand name drug, and brand name drug company. The Drug Competition Act of 2002 defines key terms related to drug approval and enforcement, such as ANDA, Assistant Attorney General, brand name drug, brand name drug company, Commission, generic drug, generic drug applicant, and NDA. The term \"NDA\" refers to a New Drug Application under the Federal Food, Drug, and Cosmetic Act. SEC. 5. NOTIFICATION OF AGREEMENTS. Generic drug applicants and brand name drug companies must file agreements regarding the manufacture, marketing, or sale of the brand name and generic drugs before the generic drug enters the market. Generic drug applicants and brand name drug companies must file agreements related to the manufacture, marketing, or sale of the drugs. The agreement text must be submitted to the Assistant Attorney General and the Commission, excluding agreements concerning raw material supplies, equipment contracts, and employment or consulting contracts. Generic drug applicants and brand name drug companies must file agreements related to the manufacture, marketing, or sale of the drugs, excluding raw material supplies, equipment contracts, employment, consulting, packaging, and labeling contracts. Any other related agreements must also be filed, even if not reduced to text, with written descriptions provided if necessary. The company must file written descriptions of non-textual agreements to reveal all terms. Filing deadlines for agreements under section 5 are within 10 business days. Information filed is exempt from disclosure under section 552 of title 5, except for administrative or judicial actions. Enforcement measures are in place. SEC. 8. ENFORCEMENT. Any brand name drug company or generic drug applicant failing to comply with this Act may face a civil penalty of up to $11,000 per day of violation. The penalty can be enforced by the United States or the Commission. Compliance and equitable relief can be ordered by the United States district court. SEC. 9. RULEMAKING. The Commission, with the concurrence of the Assistant Attorney General, may define terms, exempt classes, and prescribe rules in accordance with this Act. SEC. 10. SAVINGS CLAUSE.\n\nAny action taken by the Assistant Attorney General or the Commission under this Act shall not affect proceedings related to agreements between brand name and generic drug companies under other laws. Filing under this Act does not imply a violation of antitrust laws.\n\nSEC. 11. EFFECTIVE DATE.\n\nThis Act will take effect 30 days after enactment and apply to agreements described in section 5 made 30 days after enactment. Attest: JERI THOMSON, Secretary."
}